Metagenomi Therapeutics Inc (MGX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.17+0.86%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Revenue stabilizes or grows from the low $1.2M level: rev -0.3 vs $1.2M.
Metagenomi is a gene editing biotech with a new license deal. Revenue fell but may stabilize near $1.2M in 2026-Q1. Analysts expect losses to shrink in 2027. The company is trying to improve revenue after big drops.
Revenue dropped sharply from $8.7M to $1.2M in recent quarters. The company lost money and missed earnings several times. Analysts expect revenue to fall about 32% next year. A key director recently resigned.
The market expects about 32% revenue decline and shrinking losses. Our fair value is near $7.51, reflecting these weak expectations.
Breaks if: EPS worsens or stays below -$1.47 in 2027
Breaks if: Additional key executives resign within 12 months
Revenue falls below $1.2M in 2026-Q1
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. MGX is currently loss-making and faces high risk, but it has stable management and is working toward important product development milestones.
The market seems to have priced in a low valuation compared to peers, indicating that expectations for MGX's performance are subdued. The current expectations gap suggests that investors are not anticipating significant improvement in the near term.
Fundamentals may remain weak in the near term, especially given the elevated risk of missing earnings expectations. However, management is focused on advancing their product pipeline and maintaining cash runway, which could stabilize operations over the next year.
The thesis hinges on MGX's ability to meet its regulatory milestones for MGX-001 and maintain its cash runway. Additionally, broader sector performance and economic conditions will play a critical role in shaping investor sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss contributed to this change. Recent financial performance remains below its industry peers, which raises concerns about future growth.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Management is focused on improving revenue performance, which has shown volatility over recent quarters.
Over the next 1 to 3 years, MGX's performance will depend on its execution against key milestones and the overall health of the healthcare sector. Not investment advice.